The Effect of Antineoplastons A10 and AS2-1 and Metabolites of Sodium Phenylbutyrate on Gene Expression in Glioblastoma Multiforme — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
The Effect of Antineoplastons A10 and AS2-1 and Metabolites of Sodium Phenylbutyrate on Gene Expression in Glioblastoma Multiforme
Department of Cell and Molecular Biology, Burzynski Research Institute Inc., Stafford, TX, USA
,
Department of Cell and Molecular Biology, Burzynski Research Institute Inc., Stafford, TX, USA
1 Department of Cell and Molecular Biology, Burzynski Research Institute Inc., Stafford, TX, USA
2 Department of Cell and Molecular Biology, Burzynski Research Institute Inc., Stafford, TX, USA
Antineoplastons are peptide and amino acid derivatives that occur naturally in the human body. They inhibit the growth of neoplastic cells without growth inhibition of normal cells. Phenylacetylglutaminate (PG) is an active ingredient of antineoplastons A10 and AS2-1 (ANP) and is also a metabolic by-product of phenylbutyrate (PB). The formulation of antineoplaston AS2-1 is a 4:1 mixture of phenylacetate (PN) and PG. Antineoplaston A10 is a 4:1 mixture of PG and isoPG. This study investigates the molecular mechanism of action of PG and PN. The Human U87 glioblastoma (GBM) cell line was used as the model system in this study. A total human gene array screen using the Affymetrix Human Genome plus 2.0 oligonucleotide arrays was performed using mRNA derived from U87 cells exposed to PG and PN. Pathway analysis was performed to allow the visualization of effect on metabolic pathways and gene interaction networks. Our preliminary results indicate that PG and PN interrupt signal transduction in RAS/MAPK/ERK and PI3K/AKT/PTEN pathways, interfere with cell cycle, decrease metabolism and promote apoptosis in human U87 GBM cells. The effect on multiple cellular pathways and targets, suggests that ANP and PB are promising candidates for clinical studies in GBM.
Burzynski, S. (1968) Investigations on Amino Acids and Peptides in Blood Serum of Healthy People and Patients with Chronic Renal Insufficiency. Medical Academy, Lublin.
Burzynski, S. (1969) Investigations on Unknown Ninhydrin-Reacting Substances in Human Blood Serum. I. Attempts at Identification of Three Such Substances. Experientia, 25, 490-491. http://dx.doi.org/10.1007/BF01900774
Burzynski, S.R. (1973) Biologically Active Peptides in Human Urine: I. Isolation of a Group of Medium-Sized Peptides. Physiological Chemistry and Physics, 5, 437-447.
Burzynski, S.R., Ungar, A.L. and Lubanski, E. (1974) Biologically Active Peptides in Human Urine: II. Effect on Intestinal Smooth Muscle and Heart. Physiological Chemistry and Physics, 6, 457-468.
Burzynski, S.R., Loo, T.L., Ho, D.H., Rao, P.N., Georgiades, G. and Kratzenstein, H. (1978) Biologically Active Peptides in Human Urine: III. Inhibitors of the Growth of Leukemia, Osteosarcoma and HeLa Cells. Physiological Chemistry and Physics, 8, 13-22.
Burzynski, S.R. (1976) Antineoplastons: Biochemical Defense against Cancer. Physiological Chemistry and Physics, 8, 275-279.
Burzynski, S.R. (1986) Antineoplastons—History of the Research (I). Drugs under Experimental and Clinical Research, 12, 1-9.
Burzynski, S.R. (2004) The Present State of Antineoplaston Research (1). Integrative Cancer Therapies, 3, 47-58. http://dx.doi.org/10.1177/1534735403261964
Bartek, J., Ng, K., Fischer, W., Carter, B. and Chen, C. (2012) Key Concepts in Glioblastoma Therapy. Journal of Neurology, Neurosurgery Psychiatry, 83, 753-760. http://dx.doi.org/10.1136/jnnp-2011-300709
Burzynski, S.R. (1995) Potential of Antineoplastons in Diseases of Old Age. Drugs Aging, 7, 157-167. http://dx.doi.org/10.2165/00002512-199507030-00001
Ostrom, Q.T., Gittleman, H.R., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N.E., Kruchko, C. and Barnholtz-Sloan, J.S. (2013) CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States 2006-2010. Neuro-Oncology, 15, ii1-ii56. http://dx.doi.org/10.1093/neuonc/not151
Newton, H.B. (1994) Primary Brain Tumors: Review of Etiology, Diagnosis, and Treatment. American Family Physician, 49, 787-797.
Buckner, J.C., Brown, P.D., O’Neill, B.P., Meyer, F.B., Wetmore, C.J. and Uhm, J.H. (2007) Central Nervous System Tumors. Mayo Clinic Proceedings, 82, 1271-1286. http://dx.doi.org/10.4065/82.10.1271
CGAR Network (2008) Comprehensive Genomic Characterization Defines Human Glioblastoma Genes and Core Pathways. Nature, 455, 1061-1068. http://dx.doi.org/10.1038/nature07385
Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.A., Jones, D.T.W., Konermann, C., et al. (2012) Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. Cancer Cell, 22, 425-437. http://dx.doi.org/10.1016/j.ccr.2012.08.024
Kim, Y.W., Koul, D., Kim, S.H., Lucio-Eterovic, A.K., Freire, P.R., Yao, J., Wang, J., Almeida, J.S., Aldape, K. and Alfred Yung, W.K. (2013) Identification of Prognostic Gene Signatures of Glioblastoma: A Study Based on TCGA Data Analysis. Neuro-Oncology, 15, 829-839. http://dx.doi.org/10.1093/neuonc/not024
Maitland, M.L. and Schilsky, R.L. (2011) Clinical Trials in the Era of Personalized Oncology. CA: A Cancer Journal for Clinicians, 61, 365-381. http://dx.doi.org/10.3322/caac.20135
de Tayrac, M., Aubry, M., Saikali, S., Etcheverry, A., Surbled, C., Guenot, F., et al. (2011) A 4-Gene Signature Associated with Clinical Outcome in High-Grade Gliomas. Clinical Cancer Research, 17, 317-327. http://dx.doi.org/10.1158/1078-0432.CCR-10-1126
Burzynski, S.R. (2006) Treatments for Astrocytic Tumors in Children: Current and Emerging Strategies. Pediatric Drugs, 8, 167-168. http://dx.doi.org/10.2165/00148581-200608030-00003
Burzynski, S.R., Janicki, T.J., Burzynski, G.S. and Marszalek, A. (2014) The Response and Survival of Children with Recurrent Diffuse Intrinsic Pontine Glioma on Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Brainstem Glioma. Child’s Nervous System. http://link.springer.com/article/10.1007/s00381-014-2401-z
Burzynski, S.R., Janicki, T.J., Burzynski, G.S. and Marszalek, A. (2014) A Phase II Study of Antineoplastons A10 and AS2-1 in Children with High-Grade Glioma. Final Report (Protocol BT-06) and Review of Recent Trials. Journal of Cancer Therapy, 5, 565-577. http://dx.doi.org/10.4236/jct.2014.56065
Burzynski, S.R., Janicki, T.J. and Burzynski, G.S. (2014) A Phase II Study of Antineoplastons A10 and AS2-1 in Adult Patients with Recurrent Glioblastoma Multiforme. Final Report (Protocol BT-21). Journal of Cancer Therapy, in press.
Burzynski, S.R., Janicki, T.J., Burzynski, G.S. and Marszalek, A. (2014) A Phase II Study of Antineoplastons A10 and AS2-1 in Children with Recurrent Refractory or Progressive Primary Brain Tumors. Finalr Report (Protocol BT-22). Journal of Cancer Therapy, in press.
Burzynski, S.R., Janicki, T.J. and Burzynski, G.S. (2014) Recurrent Glioblastoma Multiforme, a Strategy for Long Term Survival. Journal of Cancer Therapy, in press.
Brusilow, S.W., Danney, M., Waber, L.J., Batshaw, M., Burton, B., Levitsky, L., Roth, K., McKeethren, C. and Ward, J. (1984) Treatment of Episodic Hyperammonemia in Children with Inborn Errors of Urea Synthesis. New England Journal of Medicine, 310, 1630-1634. http://dx.doi.org/10.1056/NEJM198406213102503
Iannitti, T. and Palmieri, B. (2011) Clinical and Experimental Applications of Sodium Phenylbutyrate. Drugs in R & D, 11, 227-249. http://dx.doi.org/10.2165/11591280-000000000-00000
Burzynski, S.R. (2006) Targeted Therapy for Brain Tumors. In: Yang, A.V., Ed., Brain Cancer Therapy and Surgical Interventions, Horizons in Cancer Research, Vol. 27, Nova Science Publishers, Inc., Hauppauge, 77-11.
Patil, S.S., Burzynski, S.R., Mrowczynski, E., Grela, K. and Chittur, S.V. (2012) Phenylacetylglutaminate and Phenylacetate in Combination Upregulate VDUP1, Cause Cell Cycle Blockade and Apoptosis in U87 Glioblastoma Cells. Journal of Cancer Therapy, 3, 192-200. http://dx.doi.org/10.4236/jct.2012.33028
Malumbres, M. and Barbacid, M. (2003) RAS Oncogenes: The First 30 Years. Nature Reviews Cancer, 3, 459-465. http://dx.doi.org/10.1038/nrc1097
Newton, H.B. (2004) Molecular Neuro-Oncology and Development of Targeted Therapeutic Strategies for Brain Tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and Angiogenesis. Expert Review of Anticancer Therapy, 4, 105-128. http://dx.doi.org/10.1586/14737140.4.1.105
Fujii, T., Nakamura, A.M., Yokoyama, G., Yamaguchi, M., Tayama, K., Miwa, K., et al. (2005) Antineoplaston Induces G1 Arrest by PKCalpha and MAPK Pathway in SKBR-3 Breast Cancer Cells. Oncology Reports, 14, 489-494.
Deschenes-Simard, X., Kottakis, F., Meloche, S. and Ferbeyre, G. (2014) ERKs in Cancer: Friends or Foes? Cancer Research, 74, 412-419. http://dx.doi.org/10.1158/0008-5472.CAN-13-2381
Vivanco, I. and Sawyers, C.L. (2002) The Phosphatidylinositol 3-Kinase AKT Pathway in Human Cancer. Nature Reviews Cancer, 2, 489-501. http://dx.doi.org/10.1038/nrc839
Bjornsti, M.A. and Houghton, P.J. (2004) The TOR Pathway: A Target for Cancer Therapy. Nature Reviews Cancer, 4, 335-348. http://dx.doi.org/10.1038/nrc1362
Sonoda, Y., Ozawa, T., Aldape, K.D., Deen, D.F., Berger, M.S. and Pieper, R.O. (2001) Akt Pathway Activation Converts Anaplastic Astrocytoma to Glioblastoma Multiforme in a Human Astrocyte Model of Glioma. Cancer Research, 61, 6674-6678.
Mills, G.B., Lu, Y. and Kohn, E.C. (2001) Linking Molecular Therapeutic to Molecular Diagnostics: Inhibition of the FRAP/RAFT/TOR Component of the PI3K Pathway Preferentially Blocks PTEN Mutant Cells in Vitro and in Vivo. Proceedings of the National Academy of Sciences of the United States of America, 98, 10031-10033. http://dx.doi.org/10.1073/pnas.191379498
Nishiyama, A., Matsui, M., Iwata, S., Hirota, K., Masutani, H., Nakamura, H., Takagi, Y., Sono, H., Gon, Y. and Yodoi, J. (1999) Identification of Thioredoxin-Binding Protein-2/Vitamin D3 Up-Regulated Protein 1 as a Negative Regulator of Thioredoxin Function and Expression. Journal of Biological Chemistry, 274, 21645-21650. http://dx.doi.org/10.1074/jbc.274.31.21645
Han, S.H., Jeon, J.H., Ju, H.R., Jung, U., Kim, K.Y., Yoo, H.S., et al. (2003) VDUP1 Upregulated by TGF-β1 and 1,25-Dihydroxy-Vitamin D3 Inhibits Tumor Cell Growth by Blocking Cell-Cycle Progression. Oncogene, 22, 4035-4046.http://dx.doi.org/10.1038/sj.onc.1206610
Massague, J. (2004) G1 Cell-Cycle Control and Cancer. Nature, 432, 298-306. http://dx.doi.org/10.1038/nature03094
Pelengaris, S., Khan, M. and Evan, G. (2002) c-MYC: More than Just a Matter of Life and Death. Nature Reviews Cancer, 2, 764-776. http://dx.doi.org/10.1038/nrc904
Brown, J.M. and Attardi, L.D. (2005) The Role of Apoptosis in Cancer Development and Treatment Response. Nature Reviews Cancer, 5, 231-237.
Ghobrial, I.M., Witzig, T.E. and Adjei, A.A. (2005) Targeting Apoptosis Pathways in Cancer Therapy. CA: A Cancer Journal for Clinicians, 55, 178-194. http://dx.doi.org/10.3322/canjclin.55.3.178
Hueber, A.O., Zornig, M., Lyon, D., Suda, T., Nagata, S. and Evan, G.I. (1997) Requirement for the CD95 Receptor-Ligand Pathway in c-Myc-Induced Apoptosis. Science, 278, 1305-1309. http://dx.doi.org/10.1126/science.278.5341.1305
Hockenbery, D., Nunez, G., Milliman, C., Schreiber, R.D. and Korsmeyer, S.J. (1990) Bcl-2 Is an Inner Mitochondrial Membrane Protein That Blocks Programmed Cell Death. Nature, 348, 334-336. http://dx.doi.org/10.1038/348334a0
Levine, A.J. (1997) p53, the Cellular Gatekeeper for Growth and Division. Cell, 88, 323-331. http://dx.doi.org/10.1016/S0092-8674(00)81871-1
el-Deiry, W.S., Harper, J.W., O’Connor, P.M., Velculescu, V.E., Canman, C.E., Jackman, J., et al. (1994) WAF1/CIP1 Is Induced in p53-Mediated G1 Arrest and Apoptosis. Cancer Research, 54, 1169-1174.
Yu, J., Zhang, L., Hwang, P.M., Rago, C., Kinzler, K.W. and Vogelstein, B. (1999) Identification and Classification of p53-Regulated Genes. Proceedings of the National Academy of Sciences of the United States of America, 96, 14517-14522. http://dx.doi.org/10.1073/pnas.96.25.14517
Lozano, G. and Zambetti, G.P. (2005) What Have Animal Models Taught Us about the p53 Pathway? Journal of Pathology, 205, 206-220. http://dx.doi.org/10.1002/path.1704
Parsons, D.W., Jones, S., Zhang, X., Lin, J.C., Leary, R.J., Angenendt, P., et al. (2008) An Integrated Genomic Analysis of Human Glioblastoma Multiforme. Science, 321, 1807-1812. http://dx.doi.org/10.1126/science.1164382
Wick, W., Weller, M., Weiler, M., Batchelor, T., Yung, A.W.K. and Platten, M. (2011) Pathway Inhibition: Emerging Molecular Targets for Treating Glioblastoma. Neuro-Oncology, 13, 566-579. http://dx.doi.org/10.1093/neuonc/nor039
Chinnaiyan, P., Kensicki, E., Bloom, G., Prabhu, A., Sarcar, B., Kahali, S., Eschrich, S., Qu, X.T., Forsyth, P. and Gillies, R. (2012) The Metabolomic Signature of Malignant Glioma Reflects Accelerated Anabolic Metabolism. Cancer Research, 72, 5878-5888.http://dx.doi.org/10.1158/0008-5472.CAN-12-1572-T
Clem, B.F. and Chesney, J. (2012) Molecular Pathways: Regulation of Metabolism by RB. Clinical Cancer Research, 18, 6096-6100. http://dx.doi.org/10.1158/1078-0432.CCR-11-3164
Dou, Q.P., Zhao, S., Levin, A.H., Wang, J., Helin, K. and Pardee, A.B. (1994) G1/S-Regulated E2F-Containing Protein Complexes Bind to the Mouse Thymidine Kinase Gene Promoter. Journal of Biological Chemistry, 269, 1306-1313.
Tommasi, S. and Pfeifer, G.P. (1997) Constitutive Protection of E2F Recognition Sequences in the Human Thymidine Kinase Promoter during Cell Cycle Progression. Journal of Biological Chemistry, 272, 30483-30490. http://dx.doi.org/10.1074/jbc.272.48.30483
Wade, M., Kowalik, T.F., Mudryj, M., Huang, E.S. and Azizkhan, J.C. (1992) E2F Mediates Dihydrofolate Reductase Promoter Activation and Multiprotein Complex Formation in Human Cytomegalovirus Infection. Molecular and Cellular Biology, 12, 4364-4374.
Dang, C.V., Le, A. and Gao, P. (2009) MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities. Clinical Cancer Research, 15, 6479-6483. http://dx.doi.org/10.1158/1078-0432.CCR-09-0889
DeBerardinis, R.J. and Cheng, T. (2009) Q’s Next: The Diverse Functions of Glutamine in Metabolism, Cell Biology and Cancer. Oncogene, 29, 313-324. http://dx.doi.org/10.1038/onc.2009.358
Wise, D.R. and Thompson, C.B. (2010) Glutamine Addiction: A New Therapeutic Target in Cancer. Trends in Biochemical Sciences, 35, 427-433. http://dx.doi.org/10.1016/j.tibs.2010.05.003
Gao, P., Tchernyshyov, I., Chang, T.C., Lee, Y.S., Kita, K., Ochi, T., et al. (2009) c-Myc Suppression of miR-23a/b Enhances Mitochondrial Glutaminase Expression and Glutamine Metabolism. Nature, 458, 762-765. http://dx.doi.org/10.1038/nature07823
Yuneva, M., Zamboni, N., Oefner, P., Sachidanandam, R. and Lazebnik, Y. (2007) Deficiency in Glutamine but Not Glucose Induces MYC-Dependent Apoptosis in Human Cells. Journal of Cell Biology, 178, 93-105. http://dx.doi.org/10.1083/jcb.200703099